ATE479438T1 - Verwendung von (s)-roscovitin zur vorbeugung und/oder behandlung von neurologischen erkrankungen - Google Patents

Verwendung von (s)-roscovitin zur vorbeugung und/oder behandlung von neurologischen erkrankungen

Info

Publication number
ATE479438T1
ATE479438T1 AT07731236T AT07731236T ATE479438T1 AT E479438 T1 ATE479438 T1 AT E479438T1 AT 07731236 T AT07731236 T AT 07731236T AT 07731236 T AT07731236 T AT 07731236T AT E479438 T1 ATE479438 T1 AT E479438T1
Authority
AT
Austria
Prior art keywords
neurological diseases
roscovitin
prevention
treatment
amino
Prior art date
Application number
AT07731236T
Other languages
English (en)
Inventor
Serge Timsit
Benedicte Menn
Laurent Meijer
Original Assignee
Neurokin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurokin filed Critical Neurokin
Application granted granted Critical
Publication of ATE479438T1 publication Critical patent/ATE479438T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • External Artificial Organs (AREA)
  • Saccharide Compounds (AREA)
AT07731236T 2006-03-30 2007-03-30 Verwendung von (s)-roscovitin zur vorbeugung und/oder behandlung von neurologischen erkrankungen ATE479438T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0602773A FR2899107B1 (fr) 2006-03-30 2006-03-30 Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
PCT/FR2007/000558 WO2007118984A1 (fr) 2006-03-30 2007-03-30 Utilisation de la ( s ) -roscovitine pour la prevention et/ou le traitement de maladies neurologiques

Publications (1)

Publication Number Publication Date
ATE479438T1 true ATE479438T1 (de) 2010-09-15

Family

ID=37054697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07731236T ATE479438T1 (de) 2006-03-30 2007-03-30 Verwendung von (s)-roscovitin zur vorbeugung und/oder behandlung von neurologischen erkrankungen

Country Status (13)

Country Link
US (1) US8318707B2 (de)
EP (1) EP1998778B1 (de)
JP (1) JP5405295B2 (de)
CN (1) CN101454009A (de)
AT (1) ATE479438T1 (de)
BR (1) BRPI0709446A2 (de)
CA (1) CA2647694C (de)
DE (1) DE602007008855D1 (de)
ES (1) ES2352520T3 (de)
FR (1) FR2899107B1 (de)
PL (1) PL1998778T3 (de)
SI (1) SI1998778T1 (de)
WO (1) WO2007118984A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
CA2706203A1 (en) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
WO2010034863A1 (es) * 2008-09-23 2010-04-01 Consejo Superior De Investigaciones Científicas (Csic) Uso de inhibidores de quinasas para la elaboración de composiciones farmacéuticas para el tratamiento de la enfermedad de parkinson, composiciones farmacéuticas y procedimiento de diagnóstico de enfermedad de parkinson
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
JP6060152B2 (ja) * 2011-05-17 2017-01-11 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 成体組織由来の安定した電気活性ニューロン
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
US12005185B2 (en) * 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
WO1999007705A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
EP0911634A1 (de) * 1997-10-24 1999-04-28 Het Nederlands Kanker Instituut Pharmazeutische Verwendungen von Regulatoren der CDK-2
JP4555476B2 (ja) * 1998-06-16 2010-09-29 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 縮合アゼピノン型サイクリン依存性キナーゼ阻害物質
DE69912808T2 (de) * 1999-12-08 2004-09-30 Centre National De La Recherche Scientifique (C.N.R.S.) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
FR2804959B1 (fr) * 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
US20040254094A1 (en) * 2000-10-11 2004-12-16 The Trustees Of University Of Pennsylvania And Board Of Regents Suppression of cyclin kinase activity for prevention and treatment of infections
US6861524B2 (en) * 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
JP2004538266A (ja) * 2001-04-27 2004-12-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド ピラゾール由来のキナーゼインヒビター
ATE478872T1 (de) 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
EP1388541A1 (de) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazine als Kinasehemmer
US20040127471A1 (en) * 2002-09-17 2004-07-01 Barry Reisberg Methods of treating age associated memory impairment (AAMI), mild cognitive impairment (MCI), and dementias with cell cycle inhibitors
DE60323876D1 (de) * 2002-12-17 2008-11-13 Centre Nat Rech Scient Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit
CA2576159A1 (en) * 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
FR2876583B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size

Also Published As

Publication number Publication date
US8318707B2 (en) 2012-11-27
SI1998778T1 (sl) 2011-01-31
EP1998778A1 (de) 2008-12-10
ES2352520T3 (es) 2011-02-21
EP1998778B1 (de) 2010-09-01
FR2899107B1 (fr) 2008-06-13
DE602007008855D1 (de) 2010-10-14
JP2009531399A (ja) 2009-09-03
WO2007118984A1 (fr) 2007-10-25
BRPI0709446A2 (pt) 2011-07-12
FR2899107A1 (fr) 2007-10-05
PL1998778T3 (pl) 2011-02-28
US20100008927A1 (en) 2010-01-14
CA2647694C (fr) 2014-12-09
JP5405295B2 (ja) 2014-02-05
CA2647694A1 (fr) 2007-10-25
CN101454009A (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
DE602007008855D1 (de) Verwendung von (s)-roscovitin zur vorbeugung und/oder behandlung von neurologischen erkrankungen
WO2009093119A3 (en) Use of serine protease inhibitors in the treatment of skin diseases
IL194843A0 (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
ATE438404T1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
ATE514435T1 (de) Verwendung eines dpp-iv-hemmers zur minderung hypoglykämischer ereignisse
MY156243A (en) Treatment for diabetes in patients inappropriate for metformin therapy
MX375132B (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico.
WO2004071447A3 (en) Substituted azole derivatives as therapeutic agents
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
IL192557A (en) Imidazole derivatives are conserved and used as ptpase inhibitors
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ATE449602T1 (de) Arzneimittel mit dobesilat-calcium zur behandlung und prophylaxe von sehnenerkrankungen
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
MY146920A (en) Aminothiazole derivatives and their uses as antibacterial agents
ATE501718T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
ATE553760T1 (de) Verwendung von alverin zur behandlung von hauterkrankungen
WO2007130419A3 (en) Histone deacetylase inhibitors for the treatment of neurodegeneration
ATE551052T1 (de) Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
DE502004010212D1 (de) Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
WO2008009655A3 (de) Medizinische verwendung von n-phenylpropenoyl-aminosäurederivaten und verwandten verbindungen
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties